

Curriculum Vitae

Name: Sabanis Chetan Dushantrao

Mob. No.: 8523068977

Email ID: pr.sabnischetan@gmail.com

Address

Near Mahadev Temple,
Mahadev Lane, Nilanga,
Tq. Nilanga, Dist. Latur,
Maharashtra.
Pin:413521

CAREER OBJECTIVE:

Currently seeking a new and challenging position in a leading pharmaceutical organization with professional experience in the pharmaceutical industry that will enable the achievement of further professional and personal goals.

PROFESSIONAL EXPERIENCE:

Present Organization	Maharashtra College of Pharmacy. Nilanga
Designation	Assistant Professor, Dept of Pharmaceutical Chemistry
Working From	July 2026 to till date
Previous Organization - IV	National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad
Designation	Research Scholar
Working From	September 2021 to November 2025
Previous Organization - III	ELC Group/PLG Group (Momaja Life Sciences), Ahmedabad (Solid Dosage Form & Parenteral Dosage Form)
Designation	Senior Executive
Working From	January 2021 to September 2021
Previous Organization - II	Gland Pharma Limited, Hyderabad (Parenteral Dosage Form: Injectable and Ophthalmic Product)
Designation	Executive
Worked From	February 2017 to December 2020
Previous Organization - I	Hetero Labs Ltd, Hyderabad (Solid Dosage Form)
Designation	Officer
Worked From	July 2015 to January 2017

DETAIL JOB PROFILE:

Previous Organization - IV
National Institute of Pharmaceutical Education and Research (NIPER)
Hyderabad

- **Research Title: Regulatory aspect and analytical approach for the determination of impurities between various marketed finished pharmaceutical products**
- **Student Presentation/ J Club (MS Pharm)**
 - ✓ Overview of various filters and their parameters
 - ✓ Overview of various analytical methods/instruments used in API characterization in dossier filing
 - ✓ ICH Q8 - Requirements for various dosage forms
 - ✓ Various regulatory site exploration
 - ✓ Various eCTD software
 - ✓ Overview of 21 CFR Parts 210 and 211 regulations
 - ✓ Overview of important regulatory guidelines
 - ✓ RTR Guideline
 - ✓ USFDA Stability question and answer
 - ✓ Controlled correspondence guidance
- **Guided MS Student for thesis work entitled “Determination of Elemental Impurities in Rosuvastatin Tablets with an Emphasis on Indian Regulations”.**
- **Completed short-term online course entitled “Awareness Course on Recent Changes in Indian and Global Regulatory Landscape.**
- **Industrial Project**
Project Title: Determination Of Residual Catalase and Monoamine Oxidase Enzyme in Pf-04349713-01 By Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis.

Collaborated Industry: HIKAL Ltd.

Research Methodology Workshop

- ✓ Completed “Joint Workshop on Clinical Research Methodology” conducted by **Novartis** (Workshop Duration 5 Months).

Previous Organization - III:

ELC Group/PLG Group (Momaja Life Sciences), Ahmedabad

(Solid Dosage Form & Parenteral Dosage Form)

• Job Responsibilities

- ✓ Review, compiling, and submission of CMC variations in a timely manner to the health agency as per regulatory requirements.
- ✓ Prepare Module 1 documents and the eCTD content plan for European submission and publication.
- ✓ Post-approval changes and product life cycle management, including variations submissions related to administrative, quality (Modules 1, 2, and 3), and safety for the European market.
- ✓ Query response raised by the regulatory authority as per regulatory requirement and their submission to the regulatory agency within set timeframes.
- ✓ Maintaining the regulatory database/ documents/ records in electronic format.
- ✓ Coordination with other departments across Europe regarding review/compilation/ submission of variations in a timely manner to the health agency.
- ✓ Providing all possible support to the Client for the maintenance of the life cycle for the product.

• Key competencies

- ✓ Awareness about Regulatory documents and filing for quality variations (Module 1, 2, and Module 3 changes)
- ✓ Well-known about various Regulatory bodies and guidelines, EU country-specific requirements for eCTD publishing
- ✓ Knowledge of eCTD-related guidelines governing regulatory submissions in eCTD format
- ✓ Worked on software and knowledge insight for viewing for publishing
(Software Name: KnowledgeNET)

Previous Organization - II: Gland Pharma Limited, Hyderabad

(Parenteral Dosage Form: Injectable and Ophthalmic Product)

• ANDA Submission and Deficiency Response:

- ✓ Submission of quality ANDA to the USFDA to get accepted without screening deficiency and swift approval to meet management expectations/business strategy.
- ✓ Participating in the team discussion
- ✓ Interaction/discussion with the Global and India Cross Functional Team to ensure timely submission of original ANDA and deficiency response.
- ✓ Communication with FDA through US Agent, including Controlled Correspondence
- ✓ FOI Request to FDA

• ANDA Life Cycle Management:

- ✓ Submission of PAS, supplement CBE/CBE-30, Annual Report, and supplement deficiency response to meet business strategy.
- ✓ Active participation in ANDA Life Cycle Management
- ✓ Effective and active communication/interaction with DMF holder/excipients vendors, and contract testing laboratories for regulatory compliance/technical requirements.
- ✓ Review of Change Controls, Annual Product Review, and other submission/GMP documents.

• Customer Support Activity:

- ✓ Active participation with applicant/customer, including submission strategy for new application, deficiency response, and Life Cycle Management

- **Other Activities:**

- ✓ Co-ordinate with and provide regulatory support to other departments, including Formulation Development, Analytical Development, Technology Transfer, Quality Assurance, Quality Control, and Labelling.
- ✓ Review of submission documents, including Batch Manufacturing and Packaging Documents, Raw Material, API/Finished Product Specification and Test Methods, Process Validation Documents, and In-process Specifications etc.
- ✓ Review of Change Controls and other submission documents.
- ✓ Co-ordinate meetings between site colleagues for a path forward and better coordination

**Previous Organization - I: Hetero Labs Ltd, Hyderabad
(Solid Oral Dosage Form: ROW Market)**

- **Deliveries:**

Dossiers:

- ✓ Dispatching the new product quality dossiers, supporting documents, and samples in a framed timely manner to East African Countries (Kenya, Uganda, Tanzania, and Rwanda)
- ✓ Review of DMF as per CTD guidelines, COPP, and Manufacturing documents.
- ✓ Review of PDR as per ICH guidelines.
- ✓ Review of all technical documents, e.g. batch manufacturing record, batch Packing records, Master formula record, FP Specification, STP CoA's and Analytical method validation protocol and report with chromatograms, which are very essential to compile the dossiers as per country guidelines.
- ✓ Review of clinical study reports

Queries:

- ✓ Responding the queries in a short time (With appropriate documentation)

Variation:

- ✓ Filing variation for priority products and other products in the given timelines.

Labelling:

- ✓ Preparation of Package Inserts and Patient Information Leaflets (PIL) and
- ✓ Review the artworks as per country requirements.

Retentions:

- ✓ Preparation of annual retention documents for Uganda and Tanzania

Tender:

- ✓ Supporting tenders in East African countries by reviewing the tender

Pharmexcil:

- ✓ Filing registration fees reimbursement application to Pharmexcil on behalf of Hetero Labs Limited.

Payments:

- ✓ Preparation of Payment IOCs for product registration, variation, and Pharmexcil purposes.

SOFTWARE: PharmaReady (eCTD)

Publications

Patent Published:

- ✓ **N-((1-phenyl-9H-pyrido [3, 4-b] indol-3-yl) methyl) cinnamamides as potential anticancer agents and preparation thereof**

Patent Number: **US20190023703A1**

Inventors: Ahmed Kamal, Sathish Manda, Nagesh Narayana, Shankaraiah Nagula, **Chetan Dushantrao Sabanis**, Hari Krishna Namballa

Articles Published

- ✓ **Sabanis CD**, R Kannan B, Joga R, Simran, Kumar S, Kumar N. Potential of novel self-assembled functionalized carbon nanotubes for selective tumor targeting. **Pharmaceutical Patent Analyst**. 2022 May 1;11(3):111-7.
- ✓ Sathish M, **Dushantrao SC**, Nekkanti S, Tokala R, Thatikonda S, Tangella Y, Srinivas G, Cherukommu S, Krishna NH, Shankaraiah N, Nagesh N. Synthesis of DNA interactive C3-trans-cinnamide linked β -carboline conjugates as potential cytotoxic and DNA topoisomerase I inhibitors. **Bioorganic & medicinal chemistry**. 2018 Sep 15;26(17):4916-29.
- ✓ **Dushantrao SC**, Joga R, Kumar S. Vosoritide, a miracle drug, covering unmet need in achondroplasia: A regulatory update. **Intractable & Rare Diseases Research**. 2023 Nov 30;12(4):257-61.
- ✓ Shah S, Joga R, **Dushyantrao CS**, Kolipaka T, Khairnar P, Phatale V, Pandey G, Srivastava S, Kumar S. Paradigm of lyotropic liquid crystals in tissue regeneration. **International Journal of Pharmaceutics**. 2023 Mar 5; 634:122633.
- ✓ Tijani AO, Garg J, Frempong D, Verana G, Kaur J, **Sabanis CD**, Joga R, Kumar S, Kumar N, Puri A. Sustained drug delivery strategies for treatment of common substance use disorders: Promises and challenges. **Journal of Controlled Release**. 2022 Aug 1; 348:970-1003.
- ✓ Devi SK, Singh S , Patil SY, Devi VM, **Dushantrao SC**, Joga R, Dwivedi F, Kumar G, Jindal DK, Singh C, Dhamija I. Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape. **European Journal of Pharmaceutics and Biopharmaceutics**. 2024 Jul 1; 200:114323.
- ✓ Joga R, Pulini-Kunnel CJ, **Sabanis CD**, Simran, Kumar S, Kumar N. Highly stable, non-toxic and functionalized nanoemulsion for the early diagnosis and amelioration of cancer. **Pharmaceutical Patent Analyst**. 2022 Sep 1;11(5):155-62.
- ✓ Joga R, **Sabanis CD**, Behera HK, Simran, Kumar S, Kumar N. Photoresponsive liposomes: an alternative of ELISA for the detection of low quantities of target substances. **Pharmaceutical Patent Analyst**. 2023 Jan 1;12(1):27-35.

Book Chapter:

- ✓ Regulatory Barriers to the Marketing Authorization of Nanodrug Delivery System, Simran, Bharathi Kannan, Amruta Nandagawale, Praveena Karnati, Ramesh Joga, **Chetan Dushantrao Sabanis**, Parul Grover, Rakesh K. Sindhu, Sandeep Kumar

Book: Nanotechnology and Drug Delivery

Articles in communication:

- ✓ Mastering Biosimilar CMC breakthroughs: From formulation to market-ready product, Lodagekar, Anurag; Sartaj, Ali; Chavan, Rahul; Naik, Naresh; **Sabnis, Chetan**; Kommineni, Nagvendra; Ghorpade, Kabirdas; Zade, Subhash; Birangal, Prashant; Swami, Shivraj, **Molecular Pharmaceutics** - Manuscript ID mp-2024-01310w

Conferences and Seminars

- ✓ Participated in a national-level seminar on “Cancer Comprehensive Approaches in Drug Discovery and Development” organized by Bombay University and presented a poster on “Oncoproteomics: New Trends in Analytical Techniques.”
- ✓ Participated in a two-day national seminar on “Ecofriendly Synthesis of Organic Compounds” sponsored by UGC and presented a poster on “Microwave Assisted Preparation of Carbon Nanotube with Multiple Functionality, won the second prize for that.
- ✓ Participated in UGC Sponsored National Conference on Nanotechnology-2012 and presented a poster
- ✓ Participated in the 5th regional level TECHNICAL PAPER PRESENTATION CONTEST at Nanded College of Pharmacy, Nanded
- ✓ Participated in a one-day seminar on Elemental impurity assessment, organized by USP India Ltd.

ACADEMIC CREDENTIALS:

Sr.No.	Description	Board/university	Year	Percentage/C.G.PA
1.	MS Pharm (Medicinal chemistry)	NIPER, Hyderabad	2013-15	7.88
2.	B. Pharmacy	S.R.T.M.U.Nanded	2009-13	75.61%
3.	Class XII	Maharashtra State Board	2008-09	77.17%
4.	Class X	Maharashtra State Board	2006-07	73.38%
5.	PGDip in Patent Laws	NALSAR University of Law, Hyderabad	2014-15	A Grade
6.	Research Scholar	NIPER, Hyderabad	Sept 2021- Nov 2025	-

PERSONAL DETAILS:

- ✓ **Date of Birth:** November 21, 1991
- ✓ **Father's name:** Mr. Sabanis Dushant Rangrao
- ✓ **Languages known:** Marathi, English, Hindi
- ✓ **Marital Status:** Married.

DECLARATION:

I hereby declare that the details provided by me are correct and I take full responsibility of those furnished above.

PLACE: Nilanga

DATE:

Sabanis Chetan Dushantrao